Rapid health technology assessment of baloxavir marboxil in the treatment of influenza
- VernacularTitle:玛巴洛沙韦治疗流行性感冒的快速卫生技术评估
- Author:
Yue WU
1
;
Qiting CHEN
2
;
Fangzhao CHEN
1
;
Chaolin ZHUO
2
;
Wei LIU
1
;
Xuejuan LI
1
;
Zebin CHEN
1
Author Information
1. Dept. of Pharmacy，Shenzhen Children’s Hospital，Guangdong Shenzhen 518038，China
2. Dept. of Integrated Traditional Chinese and Western Medicine，Shenzhen Second People’s Hospital，Guangdong Shenzhen 518035，China
- Publication Type:Journal Article
- Keywords:
baloxavir marboxil;
influenza;
rapid health technology assessment;
effectiveness;
safety;
economy
- From:
China Pharmacy
2023;34(19):2402-2408
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluate the effectiveness， safety and economy of baloxavir marboxil in the treatment of influenza， and to provide evidence-based reference for the introduction of new drugs in hospitals and clinical medication decisions. METHODS Retrieved from PubMed， Embase， Web of Science， Cochrane Library， Epistemonikos， CBM， CNKI， VIP， Wanfang database， official websites and relevant databases of health technology assessment （HTA） institutions， the results of the included studies were descriptively analyzed after literature screening， data extraction and quality evaluation. RESULTS A total of 11 studies were included， involving 6 systematic reviews/meta-analyses and 5 pharmacoeconomic studies. Compared with placebo， baloxavir marboxil significantly shortened the time to alleviation of symptoms （TTAS） and time to resolution of fever （TTRF）， reduced the virus titer change from baseline at 24 h and 48 h after treatment and the incidence of bronchitis， with statistical significance （P＜ 0.05）. Compared with neuraminidase inhibitors （NAIs）， there were no significant differences in shortening TTRF and reducing the incidence of complications， pneumonia and bronchitis （P＞0.05）. The majority of studies suggested that there were no significant differences in shortening TTAS （P＞0.05）. Only very low-quality literature suggested that baloxavir marboxil could significantly reduce the virus titer change from baseline at 24 h and 48 h after treatment. In terms of safety， the incidences of adverse events （AEs） and drug-related adverse events （DRAEs） induced by baloxavir marboxil showed no significant differences， compared with peramivir and zanamivir （P＞0.05）. Some studies considered that the incidences of AEs and DRAEs with baloxavir marboxil were lower than placebo， oseltamivir and laninamivir. Compared with oseltamivir in China and laninamivir in Japan， baloxavir marboxil showed cost-effectiveness advantages. CONCLUSIONS Compared with placebo， baloxavir marboxil has good efficacy， safety and economy. Compared with NAIs （oseltamivir）， baloxavir marboxil has good economic advantages in China， but further high-quality studies are still needed regarding its safety and efficacy.
